PMID- 18272009 OWN - NLM STAT- MEDLINE DCOM- 20080325 LR - 20240117 IS - 1532-429X (Electronic) IS - 1097-6647 (Print) IS - 1097-6647 (Linking) VI - 10 IP - 1 DP - 2008 Jan 22 TI - Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. PG - 5 LID - 10.1186/1532-429X-10-5 [doi] AB - BACKGROUND: Trastuzumab (Herceptin), an antagonist to the human epidermal growth factor 2 (HER2) receptor significantly decreases the rates of breast cancer recurrence and mortality by 50%. Despite therapeutic benefits, the risk of cardiotoxicity with trastuzumab ranges from 10-15% when administered sequentially following anthraycline chemotherapy. Little is known about the utility of cardiac magnetic resonance (CMR) in the assessment of trastuzumab mediated cardiomyopathy. METHODS AND RESULTS: Between 2005-2006 inclusive, 160 breast cancer patients were identified at a single tertiary care oncology centre. Of the total population, 10 patients (mean age 40 +/- 8 years) were identified with trastuzumab induced cardiomyopathy, based on a LVEF less than 40% on serial MUGA or echocardiography. CMR was performed in all patients to determine LV volumes, systolic function and evidence of late gadolinium enhancement (LGE). At the time of diagnosis of trastuzumab induced cardiomyopathy, the mean LVEF was 29 +/- 4%. Subepicardial linear LGE was present in the lateral portion of the left ventricles in all 10 patients. CONCLUSION: LGE-CMR is a novel way of detecting early changes in the myocardium due to trastuzumab induced cardiotoxicity. FAU - Fallah-Rad, Nazanin AU - Fallah-Rad N AD - Institute of Cardiovascular Sciences, St, Boniface Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada. umfallah@hotmail.com FAU - Lytwyn, Matthew AU - Lytwyn M FAU - Fang, Tielan AU - Fang T FAU - Kirkpatrick, Iain AU - Kirkpatrick I FAU - Jassal, Davinder S AU - Jassal DS LA - eng PT - Journal Article DEP - 20080122 PL - England TA - J Cardiovasc Magn Reson JT - Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance JID - 9815616 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antineoplastic Agents) RN - 0 (Contrast Media) RN - K2I13DR72L (Gadolinium DTPA) RN - P188ANX8CK (Trastuzumab) SB - IM MH - Adult MH - Antibodies, Monoclonal/*adverse effects MH - Antibodies, Monoclonal, Humanized MH - Antineoplastic Agents/*adverse effects MH - Breast Neoplasms/*drug therapy MH - Cardiomyopathies/*chemically induced MH - Contrast Media MH - Echocardiography MH - Female MH - Gadolinium DTPA MH - Humans MH - Magnetic Resonance Imaging/*methods MH - Middle Aged MH - Trastuzumab PMC - PMC2244612 EDAT- 2008/02/15 09:00 MHDA- 2008/03/26 09:00 PMCR- 2008/01/22 CRDT- 2008/02/15 09:00 PHST- 2007/12/18 00:00 [received] PHST- 2008/01/22 00:00 [accepted] PHST- 2008/02/15 09:00 [pubmed] PHST- 2008/03/26 09:00 [medline] PHST- 2008/02/15 09:00 [entrez] PHST- 2008/01/22 00:00 [pmc-release] AID - S1097-6647(23)01222-X [pii] AID - 1532-429X-10-5 [pii] AID - 10.1186/1532-429X-10-5 [doi] PST - epublish SO - J Cardiovasc Magn Reson. 2008 Jan 22;10(1):5. doi: 10.1186/1532-429X-10-5.